Logo
x

Search

Subscribe Now

johnson & johnson

Johnson & Johnson Reports Tremfya Pooled Analysis from GALAXI-2, 3 and QUASAR Trials

Johnson & Johnson Reports Tremfya Pooled Analysis from GALAXI-2, 3 and QUASAR Trials

  • October 11, 2024
Johnson & Johnson Completes the Acquisition of V-Wave

Johnson & Johnson Completes the Acquisition of V-Wave

  • October 11, 2024
Johnson & Johnson Highlights the Real-World Study of Erleada (Apalutamide) for Treating Metastatic Castration-Sensitive Prostate Cancer at ECOP 2024

Johnson & Johnson Highlights the Real-World Study of Erleada (Apalutamide) for Treating Metastatic Castration-Sensitive Prostate C...

  • October 3, 2024
Johnson & Johnson Submits sBLA of Darzalex Faspro Regimen to the US FDA for Newly Diagnosed Multiple Myeloma Patients

Johnson & Johnson Submits sBLA of Darzalex Faspro Regimen to the US FDA for Newly Diagnosed Multiple Myeloma Patients

  • October 1, 2024
Johnson & Johnson Reports the US FDA’s Approval of Rybrevant Plus Standard of Care to Treat EGFR-Mutated NSCLC

Johnson & Johnson Reports the US FDA’s Approval of Rybrevant Plus Standard of Care to Treat EGFR-Mutated NSCLC

  • September 20, 2024
Johnson & Johnson Reports the P-II (SunRISe-4) Study Data of TAR-200 Plus Cetrelimab to Treat Muscle-Invasive Bladder Cancer

Johnson & Johnson Reports the P-II (SunRISe-4) Study Data of TAR-200 Plus Cetrelimab to Treat Muscle-Invasive Bladder Cancer

  • September 17, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.